MARKET

AFMD

AFMD

Affimed
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.390
-0.030
-0.88%
After Hours: 3.390 0 0.00% 16:00 09/30 EDT
OPEN
3.410
PREV CLOSE
3.420
HIGH
3.480
LOW
3.310
VOLUME
393.08K
TURNOVER
--
52 WEEK HIGH
4.910
52 WEEK LOW
1.420
MARKET CAP
311.71M
P/E (TTM)
-4.8284
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Affimed to Present at Jefferies Virtual Cell Therapy Summit
Heidelberg, Germany, September 29, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that the company’s management will present at the Jefferies Virtual Cell Therapy Conference on Tuesday
GlobeNewswire · 1d ago
PLM, REAL, SPI and BEAM among after-hours movers
Gainers: [[RLGT]] +11.3%. [[PLM]] +10.1%. [[DPW]] +6.7%. [[AFMD]] +6.6%. [[REAL]] +6.4%.Losers: [[AMBO]] -16.6%. [[SPI]] -6.8%. [[BEAM]] -5.5%. [[JAMF]] -4.5%. [[ITCI]] -4.3%.
Seekingalpha · 2d ago
Are Institutions Heavily Invested In Affimed N.V.'s (NASDAQ:AFMD) Shares?
The big shareholder groups in Affimed N.V. (NASDAQ:AFMD) have power over the company. Generally speaking, as a company...
Simply Wall St. · 09/14 11:21
Affimed to Present at Upcoming Investor Conferences
Heidelberg, Germany, September 2, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that the company’s management will participate in the following investor conferences during the month
GlobeNewswire · 09/02 11:30
Billionaire Steven Cohen Pulls the Trigger on These 3 Penny Stocks
There are two sides to every coin. For penny stocks, or tickers that trade for less than $5 per share, this rings especially true. As some of the most divisive names on the Street, they are either met with resounding praise or forceful discontent.Going beyond the argument that you get more for your money
TipRanks · 08/17 20:30
The Daily Biotech Pulse: Regulatory Setback For Fennec Pharma, Ligand To Buy Pfenex, Inovio Says Phase 2/3 Coronavirus Vaccine Study Starts In September
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 10)
Benzinga · 08/11 12:20
Affimed Q2 EPS €(0.16)
Benzinga · 08/11 10:37
Affimed Q2 EPS €(0.16)
Benzinga · 08/11 10:37
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AFMD. Analyze the recent business situations of Affimed through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AFMD stock price target is 7.24 with a high estimate of 10.05 and a low estimate of 6.03.
EPS
Institutional Holdings
Institutions: 124
Institutional Holdings: 54.89M
% Owned: 59.70%
Shares Outstanding: 91.95M
TypeInstitutionsShares
Increased
42
13.17M
New
26
1.60M
Decreased
26
4.62M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.50%
Pharmaceuticals & Medical Research
+0.51%
Key Executives
Chairman - Supervisory/Independent Director
Thomas Hecht
President/Management Board
Denise Mueller
Chief Executive Officer/Management Board
Adi Hoess
Chief Financial Officer
Angus Smith
Chief Operating Officer/Management Board
Wolfgang Fischer
Chief Scientific Officer/Management Board
Arndt Schottelius
Management Board
Andreas Harstrick
Independent Director/Supervisory Board
Bernhard Ehmer
Independent Director/Supervisory Board
Ulrich Grau
Independent Director/Supervisory Board
Berndt Modig
Independent Director/Supervisory Board
Mathieu Simon
Independent Director/Supervisory Board
Ferdinand Verdonck
Supervisory Board
Annalisa Jenkins
Supervisory Board
Harry Welten
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About AFMD
Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes AFM13, AFM13 + adoptive NK cells, AFM13 + anti-PD-1, AMF24, AMF26, AMF28 and AMF32. The Company is enrolling patients into a registration-directed study of AFM13 for CD30-positive relapsed/refractory peripheral T-cell Lymphoma and into a Phase 1/2a dose escalation/expansion study of AFM24 for the treatment of advanced EGFR-expressing solid tumors. Its preclinical product candidates include AMF26 for treating multiple myeloma, as well as AMF28 and AMF32, for treating of multiple tumor targets. In addition, the Company collaborates with Genentech to develop and commercialize certain product candidates for treating multiple cancers.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Affimed NV stock information, including NASDAQ:AFMD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AFMD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AFMD stock methods without spending real money on the virtual paper trading platform.